‘Bristol Covid variant’ that may diminish vaccine efficacy discovered for first time in US
One study found Pfizer’s vaccine works against the E484K variant, but it offers slightly less efficacy
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The Bristol variant of the coronavirus has been detected for the first time in the United States, the Centers for Disease Control and Prevention (CDC) said on Wednesday.
Research into the variant shows that it has the same makeup of the Kent strain in the United Kingdom, but with an additional mutation on the E484K spike protein.
Public Health England (PHE) has deemed the Bristol variant one of the four variants of concern in the UK due to its potential impact on Covid-19 vaccines.
“E484K is currently the mutation with most evidence of causing antigenic change,” PHE said in a statement last week. “Several independent studies showing the impact of different antigenic variants have concluded E484K is among the single mutations with the greatest impact.”
Scientists have tested Pfizer’s Covid-19 vaccine against the E484K and N501Y mutations, both of which have been found in UK and South African variants. The study found the vaccine appeared to still work, but if offered slightly less efficacy against the virus.
No mutations have thus far been proven to make the coronavirus vaccines ineffective, but they have caused concerns among health professionals over how rapidly the virus has transformed. Health officials have pushed for swift vaccinations of the public to prevent a mutation arising that could severely impact the vaccine.
Dr Rochelle Walensky, the CDC director, warned about the impact of these variants during a White House coronavirus press briefing on Wednesday.
These variants could jeopardize progress, Dr Walensky said, at a time when case numbers and hospitalisations have declined in the US by about 20 per cent in a seven-day rolling average of the last week.
The first variant that caused concern from the UK was the B.1.1.7, which has now been detected in 41 states and the District of Columbia. Due to the variant’s suspected high transmissibility, experts warned it could become the country’s main mutation by March.
Now the E484K mutation was also detected in the US.
In a separate report released by the CDC on Wednesday, researchers from Zambia explained the rapid increase in Covid-19 cases in Zambia and how it contributed to the B.1.351 variant, first detected in South Africa.
“Spread of the B.1.351 variant is of public health concern because of the potential for increased transmissibility and, thus, increases in cases, hospitalisations, and deaths,” researchers wrote.
The B.1.351 variant has also been detected in several states and has characteristics that concern scientists about its potential impact on vaccine efficacy.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments